Anterior Depressions Angiographic and Clinical Outcomes Among Patients with Acute Coronary Syndromes Presenting with Anterior ST-Segment Depressions C.

Slides:



Advertisements
Similar presentations
ACTION Registry (Acute Coronary Treatment and Intervention Outcomes Network) Initial Report 1st Quarter 2007 Results Report prepared by: www. ncdr.com.
Advertisements

Patient Oriented Therapy Non STE ACS
Unstable angina and NSTEMI
Tobias Reichlin, W. Hochholzer, C. Stelzig, K. Laule, M. Potocki, K
The 80 Lead ECG Body Surface Map: Can We Detect More STEMI Than with a 12 Lead ECG? James Hoekstra MD Professor and Chairman Department of Emergency Medicine.
“ If physicians would read two articles per day out of the six million medical articles published annually, in one year, they would fall 82 centuries behind.
Montalescot G et al. Lancet 2008;372:1-9. Mid- and long-term outcomes of STEMI patients treated with prasugrel, compared with clopidogrel and undergoing.
A.Abdi,M.D. Initial Diagnosis Symptoms ECG Cardiac Biomarkers.
On behalf of the TRILOGY ACS Investigators Prasugrel versus clopidogrel for patients with unstable angina/non-ST-segment elevation myocardial infarction.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
Stanford ACS Guidelines 2003 David P. Lee, M.D. John S. Schroeder, M.D. *Donald Schreiber, M.D. Division of Cardiovascular Medicine and *Department of.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
Current and Future Perspectives on Acute Coronary Syndromes Paul W. Armstrong MD AMI Quebec Montreal October 1, 2010.
Myocardial Infarction
TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel TRITON-TIMI 38 TRITON-TIMI 38 Elliott M. Antman, MD.
Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON - TIMI 38 Stent Analysis Stephen D.
Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON - TIMI 38 Stent Analysis Stephen D.
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
ACUTE CORONARY SYNDROME (ACS). ACS Pathophysiology is that of a ruptured or eroded atheromatous plaque. Pathophysiology is that of a ruptured or eroded.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
ACS and Thrombosis in the Emergency Setting
DR. ZAHOOR 1.  A 50 year old man presents to clinic with a complaint of central chest discomfort of 2 weeks’ duration, occurring after walking for more.
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
Prehospital Fibrinolysis with Double Antiplatelet Therapy in Acute ST-Elevation Myocardial Infarction: The Clarity Ambulance Substudy Prehospital Fibrinolysis.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Author: Moldovan Carmen Co-authors: Opincariu Diana Balan Daniel University of Medicine and Pharmacy Tg. Mures Cardiology Clinic, Mures Emergency Clinical.
1 PCI in Patients Receiving Enoxaparin or UFH Following Fibrinolytic Therapy for STEMI: PCI ExTRACT-TIMI 25 C. Michael Gibson, Sabina A. Murphy, David.
Prospective, Randomized Evaluation of Immediate Versus Deferred Angioplasty in Patients with High Risk Acute Coronary Syndromes RK Riezebos 1, E Ronner.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
ACUTE CORONARY SYNDROMES Part I. Definition Acute coronary syndrome (ACS) describes a spectrum of clinical conditions ranging from ST segment elevation.
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation.
CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.
Acute Coronary Syndromes. Learning outcomes To understand the clinical spectrum of coronary disease To recognise different presentations of the disease.
Is Bivalirudin Monotherapy Sufficient for Diabetic Patients with Acute Coronary Syndrome Undergoing PCI? Frederick Feit, Steven Manoukian, Ramin Ebrahimi,
Acute Coronary Syndrome David Aymond, MD. ACS Definition: Myocardial ischemia typically due to atherosclerotic plaque rupture  Coronary thrombosis ACS.
Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center Implications of Preoperative Thienopyridine Use Prior to.
Antiplatelet Interventions in Acute Coronary Syndromes.
Coronary Heart Disease (CHD) László Tornóci Inst. Pathophysiology Semmelweis University.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.
Spectrum of Acute Coronary Syndromes: Laboratory Findings in Q-Wave AMI Creatine kinase evidence of necrosis NonePositive ECG early ST-segment depression.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Major Bleeding is Associated with Increased One-Year Mortality and Ischemic Events in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary.
Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,
Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial Alexandra J. Lansky on behalf.
TRITON TIMI-38 STEMI cohort Clopidogrel Under Fire: Is Prasugrel in Primary PCI or Recent MI Superior? Insights From TRITON-TIMI-38 Gilles Montalescot,
Dr.Ali Eshraghi MD Interventional Cardiologist Non STE ACS  Angiographic Findings: 34% 3VD 28%2VD 26%SVD 10%LMCAD Culprit lesion charactristic: eccentric,scalloped,evidence.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial Frederick Feit, Steven.
Cardiac causes of cardiac arrest
The American College of Cardiology Presented by Dr. Adnan Kastrati
The American College of Cardiology Presented by Dr. Adnan Kastrati
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Gender differences in the management of acute coronary syndrome patients: One year results from HPIAR (HP-India ACS Registry) Kunal Mahajan*, Negi PC,
The European Society of Cardiology Presented by Dr. Saman Rasoul
Intra Coronary AdjunctivE Tenecteplase During Primary PCI for STEMI:
Has acute myocardial infarction mortality hit rock bottom
Dr. Harvey White on behalf of the ACUITY investigators
Section A: Introduction
European Heart Association Journal 2007 April
The European Society of Cardiology Presented by RJ De Winter
Global Registry of Acute Coronary Events: GRACE
Implications of Preoperative Thienopyridine Use
Is Bivalirudin Monotherapy Sufficient for Diabetic Patients
Association of Troponin Elevation with Risk of Mortality in Acute Coronary Syndromes Mortality at 42 Days  % A study by Antman and.
Presentation transcript:

Anterior Depressions Angiographic and Clinical Outcomes Among Patients with Acute Coronary Syndromes Presenting with Anterior ST-Segment Depressions C. Michael Gibson, Yuri B. Pride, Satishkumar Mohanavelu, Stephen D. Wiviott, Elliott M. Antman and Eugene Braunwald AHA Scientific Sessions 2008 New Orleans Disclosure Statement: TRITON-TIMI 38 was supported by a research grant to the Brigham and Women’s Hospital from Daiichi Sankyo and Eli Lilly. None of the individual authors has any relevant conflicts to report.

Anterior Depressions BACKGROUND Rapid triage of patients with an acute coronary syndrome (ACS) to an appropriate pharmacologic and / or invasive strategy is associated with improved outcomesRapid triage of patients with an acute coronary syndrome (ACS) to an appropriate pharmacologic and / or invasive strategy is associated with improved outcomes The traditional 12-lead electrocardiogram (ECG) is one diagnostic modality in the initial evaluation of patients with chest painThe traditional 12-lead electrocardiogram (ECG) is one diagnostic modality in the initial evaluation of patients with chest pain The presence of ST-segment elevation is the key branch point in the triage to emergent reperfusion therapyThe presence of ST-segment elevation is the key branch point in the triage to emergent reperfusion therapy

Anterior Depressions BACKGROUND Anterior ST-segment depressions Unstable angina or non-ST-segment elevation myocardial infarction Risk stratification Conservative or early invasive strategy Acute thrombotic occlusion in the posterior circulation Antiplatelet and antithrombotic therapy EMERGENT REPERFUSION THERAPY

Anterior Depressions GOALS To determine the angiographic and clinical outcomes among patients presenting with ACS and isolated anterior ST-segment depression on 12-lead ECG To compare the clinician diagnosis of STEMI with subsequent angiographic evidence, such as an occluded culprit artery, and serologic evidence of myocardial necrosis To determine the diagnostic ECG-to-PCI time among patients with an occluded culprit artery

Anterior Depressions MAIN TRIAL DESIGN Double-blind ACS (STEMI or UA/NSTEMI) & Planned PCI PRASUGREL 60 mg LD/ 10 mg MD CLOPIDOGREL 300 mg LD/ 75 mg MD 1 o endpoint: CV death, MI, Stroke Duration of therapy: 6-15 months n=13,608 Diagnostic ECG Angiography / PCI

Anterior Depressions METHODS Patients with isolated anterior ST-segment depression were included in the analysis  Patients with ST-segment elevation in other arterial territories were excluded ECGs and angiograms were evaluated by local investigators

Anterior Depressions METHODS Anterior ST-segment depressions Unstable angina TFG 2/3 in culprit artery NSTEMI - Tn + Tn “STEMI” + Tn TFG 0/1 in culprit artery

Anterior Depressions METHODS Outcomes  Composite of death or MI at 30 days  Fold elevation in cardiac biomarkers As a surrogate for infarct size  Recognition of STEMI by local investigators  Time from diagnostic ECG to PCI

Anterior Depressions POPULATION 1,198 patients with isolated anterior depressions 13,608 patients enrolled in TRITON-TIMI with UA (20.2%) 641 with NSTEMI (53.5%) 314 with “STEMI” (26.2%) TFG 2/3 - Tn TFG 2/3 + Tn TFG 0/1 + Tn

Anterior Depressions BASELINE CHARACTERISTICS Characteristic“STEMI”(n=314)UA/NSTEMI(n=884)p-value Male71%65%0.054 Age, yrs (mean) Diabetes19%22%0.15 Hypertension60%71%<0.05 Hyperlipidemia50%54%0.072 Prior MI15%17%0.55 Smoker33%30%0.38 BMI, kg/m 2 (mean) CrCl, ml/min (mean)

Anterior Depressions CULPRIT ARTERY IN “STEMI”* PATIENTS n=106n=56n=152 * TFG 0/1 in culprit artery Positive cardiac biomarkers

Anterior Depressions 3-way p=0.006 CLINICAL OUTCOMES 30-day death or MI n=641n=314 n=243 TFG 2/3 - Tn TFG 2/3 + Tn TFG 0/1 + Tn

Anterior Depressions INFARCT SIZE p<0.001 n=884 n=314

Anterior Depressions INFARCT SIZE BY CULPRIT ARTERY p<0.05 for all

Anterior Depressions MANAGEMENT Among patients with an occluded culprit artery and anterior ST-segment depression, only 14/314 (4.5%) were interpreted by the investigator as a STEMI The median time from baseline ECG to PCI for patients with an occluded culprit artery was 29.4 hours (IQR hours) None of the patients with an occluded artery had an ECG to PCI time <6 hours

Anterior Depressions LIMITATIONS Only patients who survived until angiography were included  Due to survival bias, this dataset may therefore underestimate the number of patients with anterior ST-segment depression who have an occluded artery ECGs were read locally, not by a core laboratory, and so subtle ST-segment elevation cannot be excluded

Anterior Depressions CONCLUSIONS More than a quarter of patients with ACS who present with isolated anterior ST- segment depressions in TRITON-TIMI 38 had an occluded culprit artery and positive cardiac biomarkers The occluded artery was most often the left circumflex artery

Anterior Depressions CONCLUSIONS Patients with anterior ST-segment depression and an occluded culprit artery had significantly larger infarcts and worse short-term clinical outcomes These ECG findings frequently went unrecognized as evidence of a possibly occluded culprit artery This suggests the need for improved methods to identify patients with isolated anterior ST-segment depression who have an occluded artery